KEGG   DRUG: BrolucizumabHelp
Entry
D11083                      Drug                                   

Name
Brolucizumab (USAN/INN);
Brolucizumab (genetical recombination) (JAN);
Brolucizuab-dbll;
Beovu (TN)
Product
Formula
C1164H1768N310O372S8
Exact mass
26296.6724
Mol weight
26312.8665
Sequence
MEIVMTQSPS TLSASVGDRV IITCQASEII HSWLAWYQQK PGKAPKLLIY LASTLASGVP
SRFSGSGSGA EFTLTISSLQ PDDFATYYCQ NVYLASTNGA NFGQGTKLTV LGGGGGSGGG
GSGGGGSGGG GSEVQLVESG GGLVQPGGSL RLSCTASGFS LTDYYYMTWV RQAPGKGLEW
VGFIDPDDDP YYATWAKGRF TISRDNSKNT LYLQMNSLRA EDTAVYYCAG GDHNSGWGLD
IWGQGTLVTV SS
(Disulfide bridge: 24-89, 154-228)
  Type
Peptide
Remark
ATC code: S01LA06
Product: D11083<US>
Efficacy
Age-related macular degeneration therapeutic agent, Anti-VEGF antibody
  Disease
Age-related macular degeneration [DS:H00821]
Comment
Monoclonal antibody
Treatment of wet age-related macular degeneration
Target
VEGFA [HSA:7422] [KO:K05448]
  Pathway
hsa04370  VEGF signaling pathway
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 S SENSORY ORGANS
  S01 OPHTHALMOLOGICALS
   S01L OCULAR VASCULAR DISORDER AGENTS
    S01LA Antineovascularisation agents
     S01LA06 Brolucizumab
      D11083  Brolucizumab (USAN/INN) <US>
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Growth factors (RTK-binding)
    VEGFA
     D11083  Brolucizumab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11083
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11083
BRITE hierarchy
Other DBs
CAS: 1531589-13-5
PubChem: 375581030
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system